Savara (Nasdaq:SVRA) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

SVRA Aperçu des actions

Savara Inc. est une société biopharmaceutique en phase clinique qui se concentre sur les maladies respiratoires rares.

SVRA analyse fondamentale
Score flocon de neige
Évaluation	0/6
Croissance future	5/6
Performances passées	0/6
Santé financière	5/6
Dividendes	0/6

Récompenses

Earnings are forecast to grow 55.67% per year

Analyse des risques

Makes less than USD$1m in revenue ($0)

Shareholders have been diluted in the past year

Savara Inc. Concurrents

Cogent Biosciences

NasdaqGS:COGT

US$1.0b

Corbus Pharmaceuticals Holdings

NasdaqCM:CRBP

US$644.6m

Cullinan Therapeutics

NasdaqGS:CGEM

US$968.8m

Design Therapeutics

NasdaqGS:DSGN

US$252.0m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Savara
Historique des cours de bourse
Prix actuel de l'action	US$4.45
Plus haut sur 52 semaines	US$5.70
Plus bas sur 52 semaines	US$3.12
Bêta	0.99
1Variation sur 1 mois	-0.45%
Variation sur 3 mois	3.49%
Variation sur 1 an	18.67%
3Variation sur 3 ans	244.96%
Variation sur 5 ans	102.27%
Évolution depuis l'introduction en bourse	-49.20%

Nouvelles et mises à jour récentes

Savara: Today's Data 'Win' Rouses Market All Too Briefly

Jun 26

Savara: The Binary Bet On Phase 3 Data

Jun 07

Recent updates

Savara's rare lung disorder drug gets promising innovative medicine status in UK

Aug 26

Savara GAAP EPS of -$0.06 in-line

Aug 11

Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?

Jan 24

Is Savara (NASDAQ:SVRA) A Risky Investment?

Jul 05

Savara: They Failed Once, But They Are Trying Again

Jun 07

The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares

Mar 17

Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares

Feb 26

Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex

Nov 24

Savara EPS misses by $0.01

Nov 05

Rendement pour les actionnaires

	SVRA	US Biotechs	US Marché
7D	8.5%	5.3%	4.9%
1Y	18.7%	15.7%	25.6%

Rendement vs Industrie: SVRA a dépassé le secteur US Biotechs qui a rapporté 11.8 % au cours de l'année écoulée.

Rendement vs marché: SVRA a sous-performé le marché US qui a rapporté 24.9 % au cours de l'année écoulée.

Volatilité des prix

Is SVRA's price volatile compared to industry and market?
SVRA volatility
SVRA Average Weekly Movement	9.2%
Biotechs Industry Average Movement	10.6%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.2%

Cours de l'action stable: SVRA n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: SVRA's weekly volatility (9%) has been stable over the past year.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
n/a	37	Matt Pauls	www.savarapharma.com

Savara Inc. est une société biopharmaceutique en phase clinique qui se concentre sur les maladies respiratoires rares. Le principal produit candidat de la société est le molgramostim, un facteur inhalé de stimulation des colonies de granulocytes et de macrophages, qui est en phase 3 de développement pour le traitement de la protéinose alvéolaire pulmonaire auto-immune. Le siège de Savara Inc. se trouve à Langhorne, en Pennsylvanie.

Savara Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Savara se comparent-ils à sa capitalisation boursière ?
SVRA statistiques fondamentales
Capitalisation boursière	US$716.01m
Bénéfices(TTM)	-US$75.29m
Recettes(TTM)	n/a

0.0x

Ratio P/S

-9.7x

Ratio P/E

Le site SVRA est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
SVRA compte de résultat (TTM)
Recettes	US$0
Coût des recettes	US$45.63m
Marge brute	-US$45.63m
Autres dépenses	US$29.66m
Les revenus	-US$75.29m

Derniers bénéfices déclarés

Jun 30, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-0.46
Marge brute	0.00%
Marge bénéficiaire nette	0.00%
Ratio dettes/capitaux propres	26.0%

Quelles ont été les performances à long terme de SVRA?

Voir les performances historiques et les comparaisons

SVRA Aperçu des actions

Récompenses

Analyse des risques

Savara Inc. Concurrents

NasdaqGS:COGT

US$1.0b

NasdaqCM:CRBP

US$644.6m

NasdaqGS:CGEM

US$968.8m

NasdaqGS:DSGN

US$252.0m

Historique des prix et performances

Nouvelles et mises à jour récentes

Price target increased by 19% to US$10.71

Savara: Today's Data 'Win' Rouses Market All Too Briefly

Savara Inc. Announces Positive Results from the Pivotal, Phase 3 IMPALA-2 clinical trial

Savara: The Binary Bet On Phase 3 Data

Savara Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Savara Inc., Annual General Meeting, Jun 06, 2024

Recent updates

Price target increased by 19% to US$10.71

Savara: Today's Data 'Win' Rouses Market All Too Briefly

Savara Inc. Announces Positive Results from the Pivotal, Phase 3 IMPALA-2 clinical trial

Savara: The Binary Bet On Phase 3 Data

Savara Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Savara Inc., Annual General Meeting, Jun 06, 2024

Dr. Ricky Sun Notifies the Board of Directors of Savara Inc. of His Intention Not to Stand for Reelection

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis at the American Thoracic Society International Conference 2024

No longer forecast to breakeven

New minor risk - Profitability

Chairman & CEO recently sold US$396k worth of stock

Forecast to breakeven in 2026

Savara Inc. Introduces Apap Clearpath, A Gm-Csf Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis

Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?

New minor risk - Profitability

No longer forecast to breakeven

Price target increased by 7.3% to US$5.50

Price target increased by 7.5% to US$5.38

New minor risk - Shareholder dilution

New minor risk - Share price stability

Savara Inc. has completed a Follow-on Equity Offering in the amount of $79.994334 million.

Savara Inc. Completes Enrollment of Pivotal Phase 3 Impala-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis

Independent Director recently bought US$259k worth of stock

No longer forecast to breakeven

Price target increased by 21% to US$4.60

Savara Inc. Announces New Leadership Appointments

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Savara Inc. Announces New Leadership Appointments

Independent Director recently bought US$56k worth of stock

Forecast to breakeven in 2025

Independent Director recently bought US$82k worth of stock

Independent Director recently bought US$68k worth of stock

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Independent Director recently bought US$187k worth of stock

Independent Director recently bought US$142k worth of stock

Savara Announces Resignation of Badrul Chowdhury as Chief Medical Officer, Effective on September 9, 2022

Savara's rare lung disorder drug gets promising innovative medicine status in UK

Savara GAAP EPS of -$0.06 in-line

Independent Director recently bought US$138k worth of stock

Savara Inc. has completed a Follow-on Equity Offering in the amount of $60 million.

Savara Inc., Annual General Meeting, Jun 02, 2022

Price target increased to US$4.50

Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?

Independent Director recently bought US$64k worth of stock

Independent Director recently bought US$215k worth of stock

Independent Director recently bought US$176k worth of stock

Independent Director recently bought US$115k worth of stock

Is Savara (NASDAQ:SVRA) A Risky Investment?

Savara Inc. Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial

Savara Inc.(NasdaqGS:SVRA) dropped from Russell 3000E Value Index

Savara: They Failed Once, But They Are Trying Again

Independent Director recently bought US$81k worth of stock

The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares

Savara Inc. has completed a Follow-on Equity Offering in the amount of $113.011275 million.

Revenue and earnings beat expectations

Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares

Chairman & CEO recently bought US$50k worth of stock

New 90-day high: US$2.06

New 90-day high: US$1.97